cbdMD (YCBD) Stock Price, News & Analysis

Company Overview

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, hempMD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, drink mixes, and sleep, focus, and calming aids. The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name; nootropic mushroom line under the ATRx brand; and hemp derived solutions under the hempMD brand. It distributes its products through its e-commerce website, third-party e-commerce sites, select distributors and marketing partners, wholesalers, and various brick and mortar retailers in the United States. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. is headquartered in Charlotte, North Carolina.

Key Stats

• Today's Range: $0.74 to $0.80
• 50-Day Range: $0.63 to $0.97
• 52-Week Range: $0.59 to $6.54
• Volume: 143,978 shs
• Average Volume: 130,494 shs
• Market Capitalization: $6.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Buy

cbdMD Stock Analysis - MarketRank™

cbdMD scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

cbdMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

cbdMD has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

cbdMD has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.69% of the float of cbdMD has been sold short.

Short Interest Ratio / Days to Cover

cbdMD has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in cbdMD has recently increased by 35.89%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

cbdMD does not currently pay a dividend.

Dividend Growth

cbdMD does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.69% of the float of cbdMD has been sold short.

Short Interest Ratio / Days to Cover

cbdMD has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in cbdMD has recently increased by 35.89%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for YCBD on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

1 people have added cbdMD to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, cbdMD insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.10% of the stock of cbdMD is held by insiders.

Percentage Held by Institutions

Only 7.18% of the stock of cbdMD is held by institutions.

YCBD Stock Analysis - Frequently Asked Questions

How have YCBD shares performed this year?

cbdMD's stock was trading at $2.6232 at the beginning of the year. Since then, YCBD shares have decreased by 71.8% and is now trading at $0.7390.

How were cbdMD's earnings last quarter?

cbdMD, Inc. (NYSEAMERICAN:YCBD) issued its quarterly earnings results on Thursday, December, 16th. The company reported ($25.20) EPS for the quarter, missing the consensus estimate of ($16.20) by $9.00. The business had revenue of $9.79 million for the quarter. cbdMD had a negative net margin of 7.95% and a negative trailing twelve-month return on equity of 57.60%.

When did cbdMD's stock split?

Shares of cbdMD reverse split on Wednesday, May 7th 2025.The 1-8 reverse split was announced on Monday, April 21st 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 6th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Who are cbdMD's major shareholders?

Top institutional shareholders of cbdMD include Chapin Davis Inc. (1.33%) and Alesco Advisors LLC (0.77%).
View institutional ownership trends.

How do I buy shares of cbdMD?

Shares of YCBD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of cbdMD own?

Based on aggregate information from My MarketBeat watchlists, some other companies that cbdMD investors own include Village Farms International (VFF), Tilray Brands (TLRY), NVIDIA (NVDA), Roku (ROKU), Organigram Global (OGI), Bristol Myers Squibb (BMY) and Bionano Genomics (BNGO).

Company Calendar

• Last Earnings: 12/16/2021
• Today: 8/30/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Business Services
• Industry: ADVERTISING/MKTG SVCS
• Sub-Industry: Consumer Goods
• Current Symbol: NYSEAMERICAN:YCBD
• CIK: 1644903
• Web: www.cbdmd.com
• Phone: (704) 445-3060
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Price Target for cbdMD: $2.00
• High Price Target: $2.00
• Low Price Target: $2.00
• Potential Upside/Downside: +170.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.70 million
• Net Margins: -7.95%
• Pretax Margin: -7.95%
• Return on Equity: -57.60%
• Return on Assets: -14.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.56
• Quick Ratio: 0.78

Sales & Book Value

• Annual Sales: $19.48 million
• Price / Sales: 0.34
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.69 per share
• Price / Book: 1.07

Miscellaneous

• Outstanding Shares: 8,910,000
• Free Float: 8,726,000
• Market Cap: $6.58 million
• Optionable: Not Optionable
• Beta: 2.16